Welldoc Insulin Adjustment Program Approved by FDA; Fractyl to Initiate Study for Insulin-dependent T2DM Patients
Two diabetes-related news items have been observed: Welldoc announced FDA approval of an additional feature for the BlueStar platform called the Insulin Adjustment Program (IAP) and Fractyl Laboratories announced FDA approval of an Investigational Device Exemption (IDE) to initiate a study examining the effects of Revita DMR in T2DM patients treated with insulin. Below FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.